A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss
Latest Information Update: 06 Mar 2024
At a glance
- Drugs LY 3056480 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms REGAIN
- Sponsors Audion Therapeutics
Most Recent Events
- 04 Mar 2024 According to the Audion Therapeutics media release, data from this study published in Nature Communications
- 04 Mar 2024 Results published in the Audion Therapeutics Media Release
- 22 Oct 2021 Status changed from active, no longer recruiting to completed.